30 closest matches · ranked by relevance
Type 2 Diabetes · Pre-Diabetes
Primary: Percent Weight Change Through 16 Sessions — -2.4; -1.3; -1.5; -1.6 percent weight change
Type 2 Diabetes · Men
Primary: Change in Weight in Pounds — 3.8 percentage of body weight lost
Human Immunodeficiency Virus Infection · Sexually Transmitted Diseases
Primary: Self-reported Consistent Condom Use During Vaginal Intercourse in the Past 3 Months — 121; 103; 125; 93 Participants — p=.008
HIV
Primary: Condom Use/Unprotected Sex - Redefined as Sexual Risk - 12 Month Follow-up — 28; 18; 26; 40 Participants
Sexual Behavior · Alcohol Drinking · Sexual Aggression
Primary: Mean Score of Sexual Risk Intentions — 2.35; 1.67; 2.15; 1.37 score on a scale — p=<.01
Sexual Behavior
Primary: Study Feasibility Based on the Overall Recruitment Rate — 36.5 overall recruitment rate
Diabetes Mellitus, Type 2
Primary: Hemoglobin A1C — -0.20; -0.13 percent of hemoglobin A1c
Behavior · Cardiovascular Risk Factor · Influenza
Primary: Average Take-up of Preventive Services (Post-consultation) — 0.52; .71 score on a scale
Human Papillomavirus
Primary: HPV Prevalence — 61 participants
Anus Neoplasms
Primary: Willingness to Receive the Human Papillomavirus (HPV) Vaccine — 338 Participants
Obesity · Metabolic Syndrome · Lifestyle Intervention
Primary: Number and Percentage of Men Achieving 5% Weight Loss or More — 37; 51 Participants
HIV
Primary: Sexual Pleasure Scale Score for Fitted Versus Standard Condoms — 71.52; 70.13 score on a scale — p=<0.05
HIV
Primary: Sexual Behavior — 225; 163 Participants — p=0.04
Weight Loss
Primary: Mean Change in Weight by Randomized Group — -7.03; -4.14 kilograms
Hypogonadism · Atherosclerosis
Primary: Change From Baseline in Common Carotid Artery Intima-Media Thickness (IMT) — 0.877; 0.879; 0.036; 0.033 mm
HIV · Gonorrhea · Chlamydia
Primary: Participants Self-Reporting Condomless Anal Sex at Baseline and 3 Months — 304; 312; 148; 184 Participants — p=0.20
HPV Vaccine Acceptability
Primary: Change From Baseline to Post Intervention to Follow-up (up to 3 Months) After the Interventions the Number of Participants Who Have Taken the HPV Vaccine — 0; 0; 0; 0…
Rectal Cancer
Primary: Change in Serum Testosterone Levels Between Baseline and After Preoperative Radiotherapy. — 11.3; 11.9; 9.3 nmol/L — p=0.014
Substance Use · Sexual Risk
Primary: Illicit Drug Use Days — 3.04; 11.62; 2.00; 6.04 days — p=.19
HIV/AIDS and Infections · Sexual Behavior · Health Knowledge, Attitudes, Practice
Primary: Condomless Anal Intercourse or Condomless Vaginal Intercourse — 49; 50 Participants — p=0.94
Human Immunodeficiency Virus (HIV) · Sexually Transmitted Disease (STD)
Primary: Consistent (100%) Condom Use — 9; 6; 7; 7 Participants — p=<.05
Hypogonadism
Primary: Percentage of Subjects on Testosterone Treatment Achieving Target Range for Testosterone Cav (Time-averaged Concentration Over the Dosing Interval of 24 Hours) on Day…
HIV Infections
Primary: Number of Participants With Change in Number of Risky Sexual Partnerships — 32; 24; 88; 36 Participants
HIV Infections · Sexually Transmitted Diseases · Sexual Behavior
Primary: Confidence to Engage in HIV Prevention Behaviors When Engaging in Receptive Anal Sex Over Time — 1.72; 1.71; 1.73; 1.72 units on a scale
HIV Infections
Primary: Illicit Drug Use Days — 3.17; 3.10; 3.25; 2.86 Number of Days — p=0.35
Contraception Behavior
Primary: Number of Eligible Participants Who Agreed to be Enrolled in the Study — 119 participants
Dietary Habits
Primary: Variety of Fruits and Vegetables — 2.6; -1.2 types/day — p=<0.001
Benign Prostatic Hyperplasia
Primary: The Percentage of Men Given a Drug Prescription for Their Urinary Symptoms, as Recorded in Their Medical Records — 35.7 Percentage of participants
Obesity · Physical Inactivity · Diet, Healthy
Primary: Study Interest — 91 Number of people
Medication Adherence · Depressive Symptoms · Anxiety Symptoms
Primary: Antiretroviral (ART) Medication Use — .94 units on a scale